Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Upadacitinib Sustained - release Tablets

Approval Number

国药准字HJ20233125

CompanyAbbVie Deutschland GmbH & Co. KG

Registration Date

February 14, 2023

Drug Information

Generic Name

乌帕替尼缓释片

Trade Name

瑞福

Dosage Form

片剂

Strength

45mg（按C₁₇H₁₉F₃N₆O计）

Drug Type

化学药品

Registration Date

February 14, 2023

Expiry Date

February 13, 2028

Company Information

Applicant Company

Company NameAbbVie Deutschland GmbH & Co. KG

Company Address

Knollstrasse, 67061 Ludwigshafen, Germany.

Manufacturing Company

Company NameABBVIE IRELAND NL B.V.

Company Address

Manorhamilton Road, Sligo, Ireland.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

乌帕替尼缓释片 - NMPA 批准文号 | MedPath